The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of 3-alpha-androstanediol, preferably in combination with a type 5 phosphodiesterase (PDE5) inhibitor and/or a 5-HT1A agonist. The invention also relates to the use of testosterone and a 5-HT1A agonist.